Skip to content
‹ Back to IndustriesSciences

The Space Race Is Back and Heading to the Public Market

The return of the space race has more companies and investors looking for ways to get into the industry. Astra is the first rocket company since 1990 to announce it will go public, and the latest space SPAC since Virgin Galactic in 2019. The California garage startup, which now occupies a quarter-of-a-million square foot facility…

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Sciences · AstraBloombergOuter SpacePublic
Share
The Space Race Is Back and Heading to the Public Market

Key takeaways

01

The return of the space race has more companies and investors looking for ways to get into the industry.

02

Astra is the first rocket company since 1990 to announce it will go public, and the latest space SPAC since Virgin Galactic in 2019.

03

The California garage startup, which now occupies a quarter-of-a-million square foot facility…

Free workspace

Turn your Sciences expertise into content.

Record interviews, organize footage, and write with AI in a free MarketScale workspace. Qualifying companies also get one professional video edit a month. No credit card.

Start free

The return of the space race has more companies and investors looking for ways to get into the industry. Astra is the first rocket company since 1990 to announce it will go public, and the latest space SPAC since Virgin Galactic in 2019. The California garage startup, which now occupies a quarter-of-a-million square foot facility in Alameda, is valued at $2 Billion. The company provides rocket launches for $3 Million each, significantly less than that of SpaceX and Rocket Lab. Watch Emily Chang’s report above or read the transcript below.

From home garage to full fledged rocket company, Astra is the latest upstart looking to make its name in the space race with big ambitions to ramp up to a rocket launch a day delivering things like satellites, supplies and other cutting edge technology to space within the next four years. To raise capital and fast CEO Chris Kemp plans to capitalize on the SPAC craze, and take the company public this year in a merger with Holicity, run by Billionaire and former telecom mogul Craig McCaw.

Astra would be the latest space back since virgin galactic, which merged with social capital in 2019. Astra, though, wasn’t founded by a billionaire. It started operations in a San Francisco garage with limited funding. The company now designs tests and manufactures a line of small, relatively cheap rockets at its current factory just over the Bay Bridge in Alameda, California. A former Naval base, now home to served as a jet engine research facility and gained popularity as the site of Discovery Channel’s Mythbusters.

The team occupies a quarter of a million square foot research facility where researchers, engineers and scientists can all work under one roof, eliminating the need for complex logistics. In December, successfully launched their 3.2 rocket from the Pacific spaceport complex in Kodiak, Alaska, but nearly missed its orbit target. Kemp has said some minor tweaks should resolve the issue and allow them to fly again this summer.

Spacex is currently the dominant maker of large rockets designed to carry thousands of pounds of payload to orbit. But it comes with cost, charging roughly $60 million per launch. By comparison, rocket lab, founded in New Zealand, and now headquartered in the u.s., starts at around $6 million a launch. Astra is now only capable of smaller payloads than both companies, but will charge just $3 million per launch over the next few years.

The first and last rocket company to go public with Orbital Sciences Corporation back in 1990. It since merged into a subsector of Northrop Grumman. Astra will be the only publicly traded company focused solely on building and launching rockets when it begins trading later this year if Kemp can execute his big vision.

As more and more players join the space race, opportunities will become abundant for investors to enter the arena. But questions still remain around when the industry starts making money. Morgan Stanley believes the global space industry could generate more than a trillion in revenue or more in 2040, up from $350 billion right now, over half the growth coming from satellite broadband technology. And as rocket launches get cheaper and more companies look to commercialize space, profitability may soon be taking off.

*Bloomberg contributed to this article

Follow us on social media for the latest updates in B2B!

Twitter – @MarketScale

Facebook – facebook.com/marketscale

LinkedIn – linkedin.com/company/marketscale

Your experts belong here

Every story in MarketScale Sciences starts with a company putting its lab directors, applications scientists, and field specialists on the record. Buyers are already reading this topic. The only question is whose experts they find.

Lab and research buyers verify before they trial, and your scientists give them something credible to verify against.

Get your team featuredSee how it works15 minutes, straight to a calendar.

About the author

S
Sciences
B2B Weekly

The week in Sciences, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free plan

You just read one Sciences expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your lab directors, applications scientists, and field specialists into the articles, video, and social content Sciences buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale workspace, up to 10 people
One professional video edit a month for qualifying companies
Media requests to your crowd, remote recording, AI writing tools
$0. No credit card. Company confirmation required.

More Sciences Insights

CDMOs’ new capacity skews stainless by liters, but single-use leads by system count

CDMOs’ new capacity skews stainless by liters, but single-use leads by system count

Contract Pharma reports bioTRAK data projecting CDMOs will install roughly 120 bioreactors by 2030. It says 71% of added volume is large-scale stainless steel, while 61% of systems are single-use.

  • 01Utilization discipline is still driving builds: BioTRAK’s Dawn Ecker told Contract Pharma expansion conversations typically start after a site is booked above ~80% for several years.

Sep 22, 2026

Pharma supplier diversification means little if every supplier uses the same airport

Pharma supplier diversification means little if every supplier uses the same airport

Biocair's Patrick Wohl argues in Pharmaceutical Commerce that life sciences firms must map airports, sea lanes, customs gateways and carriers alongside suppliers. Suppliers spread across countries can still share one air hub. The fix he describes is pre-qualified alternate routes and continuous review, with clinical trial shipments and cold-chain medicines the first cargo exposed when a corridor closes.

  • 01A supplier base spread across several countries can still be a single point of failure if every shipment routes through one airport hub or corridor; the sharper question for a logistics provider is which hubs each qualified lane actually depends on.
  • 02Gartner data cited by MD+DI gives a benchmark: 42% of procurement leaders rank supply disruption as their organization's top risk, with geopolitical issues including tariffs and regulatory changes ranking third.
  • 03A route map ages fast. Pharmaceutical Commerce published the mapping argument on July 24 and was reporting fresh Red Sea and Iran-related freight risk for pharma lanes by Aug. 10, which is the case for treating mapping as a recurring review rather than a project.

Sep 17, 2026

Resilience and Lilly Invest $750 Million to Increase U.S.-Manufactured Medicine Supply

Resilience and Lilly Invest $750 Million to Increase U.S.-Manufactured Medicine Supply

Resilience and Eli Lilly are investing $750 million to expand KwikPen injectable device production at Resilience's Cincinnati-region manufacturing facility, expected to create 400 high-skilled jobs and reach full operations by early 2027. The partnership builds on their collaboration since 2023, which has already produced over 150 million doses of Lilly medications for the U.S. market.

  • 01$750 million investment to expand Resilience's Ohio manufacturing capacity for Eli Lilly's KwikPen injectable device production
  • 02400 new high-skilled jobs expected in Cincinnati region, with full operations by early 2027
  • 03Partnership has already produced over 150 million doses of Lilly medications for the U.S. market since 2023

Sep 14, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

S
Sciences

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512